- Palmitoylethanolamide (PEA) improved function and reduced pain, stiffness, and anxiety without serious toxicity in a randomized controlled trial (RCT) of patients with knee osteoarthritis (KOA).
Why this matters
- PEA has the potential to be a natural, nontoxic, and targeted treatment option for KOA.
- RCT of 111 patients with mild to moderate knee osteoarthritis, receiving 300 mg PEA, 600 mg PEA, or placebo daily for 8 weeks.
- Function was assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).
- Funding: None disclosed.
- Efficacy at week 8, with each PEA dose compared with placebo:
- Reduction in WOMAC total score: 300 mg, P=.037; 600 mg, P=.001.
- Reduction in WOMAC pain subscore: 300 mg, P=.007; 600 mg, P<.001.>
- Reduction in WOMAC stiffness subscore: 300 mg. P=.049; 600 mg, P=.001.
- Reduction in WOMAC function subscore: 300 mg, NS; 600 mg, P=.003.
- Reduction in anxiety on the Depression Anxiety Stress Scale: 300 mg, P=.042; 600 mg, P=.043.
- No differences in erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).
- No differences in numerous biochemical and hematological parameters.
- No reports of serious toxicity.
- No reporting of nonserious adverse events.
- Single-center study.